136 related articles for article (PubMed ID: 9388135)
1. From the Food and Drug Administration.
Nightingale SL
JAMA; 1997 Dec; 278(21):1728. PubMed ID: 9388135
[No Abstract] [Full Text] [Related]
2. FDA reviews troglitazone.
Donnelly R
Diabetes Obes Metab; 1999 Mar; 1(2):65-6. PubMed ID: 11220513
[No Abstract] [Full Text] [Related]
3. Substituting for troglitazone (Rezulin).
Med Lett Drugs Ther; 2000 Apr; 42(1076):36. PubMed ID: 10803176
[No Abstract] [Full Text] [Related]
4. Hepatotoxicity of the thiazolidinediones.
Tolman KG; Chandramouli J
Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989
[TBL] [Abstract][Full Text] [Related]
5. Rezulin to be withdrawn from the market.
Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272
[No Abstract] [Full Text] [Related]
6. Rezulin pulled in the UK.
Zurlinden J
Nurs Spectr (Wash D C); 1998 May; 8(9):25. PubMed ID: 10542729
[No Abstract] [Full Text] [Related]
7. Troglitazone-associated hepatic failure.
Misbin RI
Ann Intern Med; 1999 Feb; 130(4 Pt 1):330. PubMed ID: 10068399
[No Abstract] [Full Text] [Related]
8. Troglitazone-associated hepatic failure.
Booth AM; Caldwell SH; Iezzoni JC
Am J Gastroenterol; 2000 Feb; 95(2):557-8. PubMed ID: 10685776
[No Abstract] [Full Text] [Related]
9. [Meta-analysis shows: insulin sensitizer is safe for the liver].
MMW Fortschr Med; 2002 Oct; 144(40):47. PubMed ID: 12440297
[No Abstract] [Full Text] [Related]
10. Update in endocrinology.
Whitcomb RW
Ann Intern Med; 1998 May; 128(10):871. PubMed ID: 9599203
[No Abstract] [Full Text] [Related]
11. Rapid-onset subfulminant liver failure associated with troglitazone.
Jagannath S; Rai R
Ann Intern Med; 2000 Apr; 132(8):677. PubMed ID: 10766693
[No Abstract] [Full Text] [Related]
12. Company played down drug's risks, report says.
Gottlieb S
BMJ; 2001 Mar; 322(7288):696. PubMed ID: 11264205
[No Abstract] [Full Text] [Related]
13. Fatal hepatotoxicity associated with troglitazone.
Vella A; de Groen PC; Dinneen SF
Ann Intern Med; 1998 Dec; 129(12):1080. PubMed ID: 9867776
[No Abstract] [Full Text] [Related]
14. Advisory panel hears contradictory evidence, backs keeping troglitazone on market.
Miller JL
Am J Health Syst Pharm; 1999 May; 56(9):840, 842. PubMed ID: 10344603
[No Abstract] [Full Text] [Related]
15. Rules and laws of drug hepatotoxicity.
Kaplowitz N
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):231-3. PubMed ID: 16552791
[No Abstract] [Full Text] [Related]
16. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.
Gitlin N; Julie NL; Spurr CL; Lim KN; Juarbe HM
Ann Intern Med; 1998 Jul; 129(1):36-8. PubMed ID: 9652997
[No Abstract] [Full Text] [Related]
17. Medical monitoring for pharmaceutical injuries: tort law for the public's health?
Studdert DM; Mello MM; Brennan TA
JAMA; 2003 Feb; 289(7):889-94. PubMed ID: 12588274
[TBL] [Abstract][Full Text] [Related]
18. Drug recalls underscore safety concerns.
Greene HL
Health News; 2000 May; 6(5):4. PubMed ID: 10851966
[No Abstract] [Full Text] [Related]
19. Plaintiff's attorney actively seeking out patients who have used various FDA approved medications and who "may be entitled to compensation for damages caused by these medications".
South D
J Miss State Med Assoc; 2000 Nov; 41(11):798-9. PubMed ID: 11107716
[No Abstract] [Full Text] [Related]
20. A novel antidiabetic drug, troglitazone--reason for hope and concern.
Imura H
N Engl J Med; 1998 Mar; 338(13):908-9. PubMed ID: 9516229
[No Abstract] [Full Text] [Related]
[Next] [New Search]
